Company intelligence / Profile preview

Race Oncology

Ownership: Private
Development stage: Phase 2

Overview

Race Oncology is advancing RC220 (bisantrene), a reformulated version of a previously approved chemotherapeutic. The company has completed two Phase 2 trials in relapsed/refractory AML showing 40% response rates. Currently conducting a Phase 1 trial of RC220 in combination with doxorubicin for solid tumors, with the first patient safely dosed in Q2 2025. Preclinical studies show bisantrene may protect the heart from anthracycline-induced damage while providing additional anticancer activity.

Therapeutic areas: OncologyHematology
Modalities: Small moleculesChemotherapeutics
Industry: Biotech

Drug pipeline

2 assets

bisantrene

1 more asset in the full pipeline.

Request access →

Partnerships

Sheba Medical Center (Israel)City of Hope (Los Angeles)

Beyond the preview

Go deeper on Race Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Race Oncology.

Explore the full profile